RT Journal Article
SR Electronic
T1 Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260776
DO 10.1101/2021.07.19.21260776
A1 Buyukozkan, Mustafa
A1 Alvarez-Mulett, Sergio
A1 Racanelli, Alexandra C.
A1 Schmidt, Frank
A1 Batra, Richa
A1 Hoffman, Katherine L.
A1 Sarwath, Hina
A1 Engelke, Rudolf
A1 Gomez-Escobar, Luis
A1 Simmons, Will
A1 Benedetti, Elisa
A1 Chetnik, Kelsey
A1 Zhang, Guoan
A1 Schenck, Edward
A1 Suhre, Karsten
A1 Choi, Justin J.
A1 Zhao, Zhen
A1 Racine-Brzostek, Sabrina
A1 Yang, He S.
A1 Choi, Mary E.
A1 Choi, Augustine M.K.
A1 Cho, Soo Jung
A1 Krumsiek, Jan
YR 2022
UL http://medrxiv.org/content/early/2022/02/11/2021.07.19.21260776.abstract
AB The novel coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has ravaged global healthcare with previously unseen levels of morbidity and mortality. To date, methods to predict the clinical course, which ranges from the asymptomatic carrier to the critically ill patient in devastating multi-system organ failure, have yet to be identified. In this study, we performed large-scale integrative multi-omics analyses of serum obtained from COVID-19 patients with the goal of uncovering novel pathogenic complexities of this disease and identifying molecular signatures that predict clinical outcomes. We assembled a novel network of protein-metabolite interactions in COVID-19 patients through targeted metabolomic and proteomic profiling of serum samples in 330 COVID-19 patients compared to 97 non-COVID, hospitalized controls. Our network identified distinct protein-metabolite cross talk related to immune modulation, energy and nucleotide metabolism, vascular homeostasis, and collagen catabolism. Additionally, our data linked multiple proteins and metabolites to clinical indices associated with long-term mortality and morbidity, such as acute kidney injury. Finally, we developed a novel composite outcome measure for COVID-19 disease severity and created a clinical prediction model based on the metabolomics data. The model predicts severe disease with a concordance index of around 0.69, and furthermore shows high predictive power of 0.83-0.93 in two previously published, independent datasets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJK is supported by the National Institute of Aging of the National Institutes of Health under award 1U19AG063744. SJC is supported by National Heart, Lung and Blood Institute under award K08HL138285. KS is supported by 'Biomedical Research Program' funds at Weill Cornell Medical College in Qatar, a program funded by the Qatar Foundation and multiple grants from the Qatar National Research Fund (QNRF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Weill Cornell Medicine (WCM) IRB with protocol #19-10020914.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are legal and ethical restrictions on data sharing because the Institutional Review Board of Weill Cornell Medicine did not approve public data deposition. The data set used for this study constitutes sensitive patient information extracted from the electronic health record. Accordingly, it is subject to federal legislation that limits our ability to disclose it to the public, even after it has been subjected to deidentification techniques. To request the access of the de-identified minimal dataset underlying these findings, interested and qualified researchers should contact Information Technologies & Services Department of Weill Cornell Medicine support@med.cornell.edu.